Posted by Michael Wonder on 22 Oct 2019
Moderna receives FDA fast track designation for propionic acidemia program (mRNA-3927)
22 October 2019 - mRNA-3927 is Moderna’s second rare disease program to receive fast track designation.
Moderna today announced that the U.S. FDA has granted fast track designation for mRNA-3927, its investigational mRNA therapeutic for propionic acidaemia.
The Company announced the open IND for mRNA-3927 on 30 September 2019.
